Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PAICS | P22234 | 1/20 | 0.40 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126334 | 0.87 | TDO2 (0.48) | DGAT1TDO2SLC6A4PAICSHRH1 | |
| Trifluoroacetic Acid SCHEMBL943761 | 0.86 | TDO2 (0.46) | DGAT1TDO2PAICSTIPARPFGFR3 | |
| Hydrochloric Acid SCHEMBL941675 | 0.85 | TDO2 (0.47) | DGAT1TDO2SLC6A4PAICSHRH1 | |
| Trifluoroacetic Acid SCHEMBL28530864 | 0.84 | TDO2 (0.44) | TDO2PAICSTIPARPHRH1LIPG | |
| SCHEMBL4828298 | 0.78 | CHRNB2 (0.47) | DGAT1TDO2 | |
| Trifluoroacetic Acid SCHEMBL26620566 | 0.78 | LIPG (0.49) | DGAT1PAICSLIPGEPHX2 | |
| SCHEMBL943763 | 0.78 | TDO2 (0.45) | DGAT1TDO2PAICSTIPARPHRH1 | |
| SCHEMBL27098546 | 0.76 | TDO2 (0.40) | DGAT1TDO2SLC6A4PAICSHRH1 | |
| SCHEMBL25196581 | 0.76 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL1588861 | 0.76 | DGAT1 (0.50) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | DGAT1 3643/4885TDO2 1813/4885SLC6A4 2060/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | DGAT1 3279/4885TDO2 1555/4885SLC6A4 2692/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | DGAT1 3643/4885TDO2 1813/4885SLC6A4 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.